Product Description
Mechanisms of Action: TLR7 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Brazil, South Africa, Spain, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Acquired Immunodeficiency Syndrome|HIV Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| A5374 | P2 |
Recruiting |
HIV Infections |
2026-04-29 |
|
| GS-US-382-5445 | P2 |
Active, not recruiting |
HIV Infections |
2025-03-01 |
|
| AELIX-003 | P2 |
Completed |
Acquired Immunodeficiency Syndrome|HIV Infections |
2022-10-03 |
25% |
| 2018-002125-30 | P2 |
Active, not recruiting |
HIV Infections |
2021-05-18 |